Skip to main content
Have a personal or library account? Click to login
Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses Cover

Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses

Acta Pharmaceutica
Volume 60 (2010): Issue 4 (December 2010)
By:   
Open Access
|Dec 2010
References

References

  1. B. Stewart and P. Kleihues,, IARC Press, Lyon 2003.
    Search in Google Scholar
  2. National Cancer Institute,
    Search in Google Scholar
  3. T. W. Fischer, M. A. Zmijewski, B. Zbytek, T. W. Sweatman, R. M. Slominski, J. Wortsman and A. Slominski, Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines,(2006) 665-672.
    Search in Google Scholar
  4. H. Brenner, Long-term survival rates of cancer patients achieved by the end of the 20century: a period analysis,(2001) 1131-1135; DOI: 10.1054/bjoc.2001.1905.
    Open DOISearch in Google Scholar
  5. J. L. Gajewski and R. E. Champlin,(Ed. C. M. Haskell and J. S. Berek), W. B. Saunders, Philadelphia 2001, pp. 276-295.
    Search in Google Scholar
  6. S. Bucurescu,, RG Fischer Verlag, Frankfurt am Main 2008, pp. 118-122.
    Search in Google Scholar
  7. N. dePace, Sulla scomparsa di un enorme cancro vegetante del collo dell'utero senza cura chirurgica,(1912) 82-89.
    Search in Google Scholar
  8. E. Kelly and S. J. Russel, History of oncolytic viruses: genesis to genetic engineering,(2007) 651-659; DOI: 10.1038/sj.mt.6300108.
    Open DOISearch in Google Scholar
  9. T-C. Liu and D. Kirn, Gene therapy progress and prospects cancer: oncolytic viruses,(2008) 877-884; DOI: 10.1038/gt.2008.72.
    Open DOISearch in Google Scholar
  10. K. Garber, China approves world's first oncolytic virus therapy for cancer treatment,(2006) 298-300; DOI: 10.1093/jnci/djj111.
    Open DOISearch in Google Scholar
  11. S. Meerani and Y. Yao, Oncolytic viruses in cancer therapy,(2010) 156-171.
    Search in Google Scholar
  12. Z. S. Guo, S. H. Thorne and D. L. Bartlett, Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses,(2008) 217-231; DOI: 10.1016/j.bbcam.2008.02.001.
    Search in Google Scholar
  13. S. Naik and S. J. Russel, Engineering oncolytic viruses to exploit tumor specific defects in innate immune signalling pathways,(2009) 1163-1176; DOI: 10.1517/14712590903170653.
    Open DOISearch in Google Scholar
  14. R. Diasio and A. F. LoBuglio,(Ed. J. G. Hardman, A. Goodman Gilman and L. E. Limbird), McGraw-Hill, New York, 2006, pp. 1291-1308.
    Search in Google Scholar
  15. D. J. McGeoch, J. A. Dolan, S. Donald and F. J. Rixon, Sequence determination and genetic content of the short unique region in the genome of herpes simplex virus type 1,(1985) 1-13; DOI: 10.1016/0022-2836(85)90320-1.
    Open DOISearch in Google Scholar
  16. H. M. Friedman, Immune evasion by herpes simplex virus type 1, strategies for virus survival,(2008) 103-112.
    Search in Google Scholar
  17. D. Westmoreland and J. F. Watkins, The IgG receptor induced by herpes simplex virus: studies using radioiodinated IgG,(1974) 167-178; DOI: 10.1099/0022-1317-24-1-167.
    Open DOISearch in Google Scholar
  18. J. P. G. Sissons,(Eds. D. A. Warell, T. M. Cox, J. D. Firth and E. J. Benz), Oxford University Press, New York 2003, pp. 327-341.
    Search in Google Scholar
  19. J. Sambrook and D. Russel D,, CSHL Press, Cold Spring Harbor 2006.
    Open DOISearch in Google Scholar
  20. J. Vieira and J. Messing, The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers,(1982) 259-268; DOI 10.1016/0378-1119(82)90015-4.
    Open DOISearch in Google Scholar
  21. F. Baneyx, Recombinant protein expression in Escherichia coli,(1999) 411-421; DOI: 10.1016/50958-1669(99)00003-8.
    Search in Google Scholar
  22. J. Weiss,, Wiley-VCH, Weinheim 2004, pp. 279-349.
    Open DOISearch in Google Scholar
  23. J. F. Watkins, Adsorption of sensitized sheep erythrocytes to HeLa cells infected with herpes simplex virus,(1964) 1364-1365; DOI: 10.1038/2021364a0.
    Open DOISearch in Google Scholar
  24. T. Van Dyke and T. Jacks, Cancer modeling in the modern era: progress and challenges,(2002) 135-144; DOI: 10.1016/S0092-8674(02)00621-9.
    Open DOISearch in Google Scholar
  25. D. Cervantes-Garcia, R. Ortiz-Lopez, N. Mayek-Perez and A. Rojas-Martinez, Oncolytic virotherapy,(2008) 34-45.
    Open DOISearch in Google Scholar
  26. N. Ting,, Springer, New York 2006, pp. 304-310.
    Open DOISearch in Google Scholar
  27. R. C. Rowe, P. J. Sheskey and M. E Quinn,, Pharmaceutical Press, Chicago 2009, pp. 69-301.
    Search in Google Scholar
  28. International Conference on Harmonisation, Harmonised Tripartite Guideline,, ICH, Geneve 1998;
    Search in Google Scholar
  29. International Conference on Harmonisation Harmonised Tripartite Guideline,, ICH, Geneve 1996;
    Search in Google Scholar
DOI: https://doi.org/10.2478/v10007-010-0039-2 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English, Croatian, Slovenian
Page range: 407 - 413
Published on: Dec 17, 2010
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Keywords:
cancer therapies,
Herpes simplex virus type 1 glycoproteins E and I,
antibody mediated neutralization of oncolytic viruses
Related subjects:
Pharmacy,
Pharmacy, other

© 2010 Septimiu Bucurescu, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.

Volume 60 (2010): Issue 4 (December 2010)
Previous article
Next article